219 related articles for article (PubMed ID: 17096071)
1. Hepatoid carcinoma of the pancreas producing protein induced by vitamin K absence or antagonist II (PIVKA-II) and alpha-fetoprotein (AFP).
Matsueda K; Yamamoto H; Yoshida Y; Notohara K
J Gastroenterol; 2006 Oct; 41(10):1011-9. PubMed ID: 17096071
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP.
Choi JY; Jung SW; Kim HY; Kim M; Kim Y; Kim DG; Oh EJ
World J Gastroenterol; 2013 Jan; 19(3):339-46. PubMed ID: 23372355
[TBL] [Abstract][Full Text] [Related]
3. Comparing prothrombin induced by vitamin K absence-II (PIVKA-II) with the oncofetal proteins glypican-3, Alpha feto protein and carcinoembryonic antigen in diagnosing hepatocellular carcinoma among Egyptian patients.
Abd El Gawad IA; Mossallam GI; Radwan NH; Elzawahry HM; Elhifnawy NM
J Egypt Natl Canc Inst; 2014 Jun; 26(2):79-85. PubMed ID: 24841158
[TBL] [Abstract][Full Text] [Related]
4. Immunohistologic study on the expressions of alpha-fetoprotein and protein induced by vitamin K absence or antagonist II in surgically resected small hepatocellular carcinoma.
Fujioka M; Nakashima Y; Nakashima O; Kojiro M
Hepatology; 2001 Dec; 34(6):1128-34. PubMed ID: 11732002
[TBL] [Abstract][Full Text] [Related]
5. A resected case of metachronous liver metastasis from lung cancer producing alpha-fetoprotein (AFP) and protein induced by vitamin K absence or antagonist II (PIVKA-II).
Oshiro Y; Takada Y; Enomoto T; Fukao K; Ishikawa S; Iijima T
Hepatogastroenterology; 2004; 51(58):1144-7. PubMed ID: 15239263
[TBL] [Abstract][Full Text] [Related]
6. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma.
Feng H; Li B; Li Z; Wei Q; Ren L
BMC Cancer; 2021 Apr; 21(1):401. PubMed ID: 33849479
[TBL] [Abstract][Full Text] [Related]
7. PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection.
Kim DY; Paik YH; Ahn SH; Youn YJ; Choi JW; Kim JK; Lee KS; Chon CY; Han KH
Oncology; 2007; 72 Suppl 1():52-7. PubMed ID: 18087182
[TBL] [Abstract][Full Text] [Related]
8. Des-gamma carboxy prothrombin (PIVKA-II) and alpha-fetoprotein producing gastric cancer with multiple liver metastases.
Takahashi Y; Inoue T
Pathol Int; 2003 Apr; 53(4):236-40. PubMed ID: 12675768
[TBL] [Abstract][Full Text] [Related]
9. [Diagnostic value of serum alpha-fetoprotein, alpha-fetoprotein variant and abnormal prothrombin in primary hepatocellular carcinoma].
Hu RZ; Zhao SQ; Shen B; Guo GB
Zhonghua Gan Zang Bing Za Zhi; 2019 Aug; 27(8):634-637. PubMed ID: 31594082
[No Abstract] [Full Text] [Related]
10. Stereotactic radiotherapy for hepatocellular carcinoma induced by hepatitis C and the relationships of changes in carbohydrate antigen 19-9 with AFP and PIVKA-II.
Maebayashi T; Ishibashi N; Aizawa T; Sakaguchi M; Okada M
Cancer Radiother; 2021 May; 25(3):242-248. PubMed ID: 33455875
[TBL] [Abstract][Full Text] [Related]
11. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion.
Poté N; Cauchy F; Albuquerque M; Voitot H; Belghiti J; Castera L; Puy H; Bedossa P; Paradis V
J Hepatol; 2015 Apr; 62(4):848-54. PubMed ID: 25450201
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA.
Wu J; Xiang Z; Bai L; He L; Tan L; Hu M; Ren Y
Cancer Biomark; 2018; 23(2):235-242. PubMed ID: 30103302
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic performance of tumor markers AFP and PIVKA-II in Chinese hepatocellular carcinoma patients.
Huang S; Jiang F; Wang Y; Yu Y; Ren S; Wang X; Yin P; Lou J
Tumour Biol; 2017 Jun; 39(6):1010428317705763. PubMed ID: 28621228
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of PIVKA-II in prediction and early detection of hepatocellular carcinoma: a nested case-control study in Chinese patients.
Yu R; Xiang X; Tan Z; Zhou Y; Wang H; Deng G
Sci Rep; 2016 Oct; 6():35050. PubMed ID: 27731353
[TBL] [Abstract][Full Text] [Related]
15. [The value of serum abnormal prothrombin in clinical application of hepatocellular carcinoma].
Zhang JW; Guan LY; E CY; Yang JH; Xuan W; Meng ZH; Li W
Zhonghua Wai Ke Za Zhi; 2020 Oct; 58(10):776-781. PubMed ID: 32993265
[No Abstract] [Full Text] [Related]
16. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group.
Ishii M; Gama H; Chida N; Ueno Y; Shinzawa H; Takagi T; Toyota T; Takahashi T; Kasukawa R
Am J Gastroenterol; 2000 Apr; 95(4):1036-40. PubMed ID: 10763956
[TBL] [Abstract][Full Text] [Related]
17. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients.
Lim TS; Kim DY; Han KH; Kim HS; Shin SH; Jung KS; Kim BK; Kim SU; Park JY; Ahn SH
Scand J Gastroenterol; 2016 Mar; 51(3):344-53. PubMed ID: 26340708
[TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels.
Kang SH; Kim DY; Jeon SM; Ahn SH; Park JY; Kim SU; Kim JK; Lee KS; Chon CY; Han KH
Eur J Gastroenterol Hepatol; 2012 Jul; 24(7):849-56. PubMed ID: 22495400
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma.
Park SJ; Jang JY; Jeong SW; Cho YK; Lee SH; Kim SG; Cha SW; Kim YS; Cho YD; Kim HS; Kim BS; Park S; Bang HI
Medicine (Baltimore); 2017 Mar; 96(11):e5811. PubMed ID: 28296720
[TBL] [Abstract][Full Text] [Related]
20. Clinical evaluation of plasma des-gamma-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes.
Kasahara A; Hayashi N; Fusamoto H; Kawada Y; Imai Y; Yamamoto H; Hayashi E; Ogihara T; Kamada T
Dig Dis Sci; 1993 Dec; 38(12):2170-6. PubMed ID: 7505217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
